Around 4% of patients have colorectal cancer and most of them present with metastases at surgery. These are indications of a poorer outcome; however, 5-year survival rates are up to 80% if curative resection is feasible. The stage at the time of presentation is the most important prognostic factor.
Although there may be a higher incidence of [colorectal cancer](https://www.withpower.com/clinical-trials/colorectal-cancer) in people with ulcerative colitis, patients should be encouraged to develop an awareness of the signs, since the colon is a key organ for cancer. Symptoms that can help in the early recognition of cancer may include colorectal bleeding or stool of irregular composition.
Very few people use these medications despite ample evidence and research showing that they are effective. Most people prefer surgery rather than any other treatment.
Environmental factors may contribute to [colorectal cancer](https://www.withpower.com/clinical-trials/colorectal-cancer) as they are to lung cancer. For a cancer to become malignant, it is likely that genetic lesions occur, some of which are due to environmental stresses. This may result in the dysregulation of the cell cycle and the activation of genes involved in cellular proliferation and survival in colorectal cancer. Smoking and alcohol add to the risk associated with these environmental risk factors.
More than 5 million people in the United States are expected to be diagnosed with [colorectal cancer](https://www.withpower.com/clinical-trials/colorectal-cancer) in 2012, but more than 4 million would die from the disease. The lifetime risk of developing colorectal cancer is 3% in adults, and almost 9% in people with family history of cancer.\n
Colorectal resection for stage 3 or node metastases is curative in approximately 35% of cases. Patients with distant metastases have a worse survival and often do not progress as rapidly or reach stage 3 as those who underwent curative resections.
Age is a significant risk factor for [colorectal cancer](https://www.withpower.com/clinical-trials/colorectal-cancer). It is important to know when and how many people are diagnosed with colorectal cancer and to implement cancer screening programs.
Results from a recent clinical trial of this first study are encouraging and a significant effect was noticed in decreasing TCI, LDL, triacylglycerol and total cholesterol concentration. Omega-3 fatty acids could constitute a new class of drugs for the treatment and prevention of dyslipidemia. However, further studies are needed to confirm these efficacy and tolerance data.
There was a lot of new information presented at the ASCRS, which was a very beneficial meetings for all of us, the physicians. The new discoveries regarding the risk factors of colorectal cancer and the treatment of colorectal tumor were discussed by the doctors and other leading scientists in the field. At the end of the meeting a question and answer session was held. It was an open-minded forum to discuss the latest research data for colorectal cancer. It became a place to hear opinions and to learn things not just the facts. These facts are so important to understand. There is much more to know about colorectal cancer.
The benefits of consuming omega-3 fatty acid ethyl esters, which are commonly found in fish oil supplements, for treatment of colorectal disease should be weighed with safety concerns and must be assessed by a clinician with experience.
Oncology is a very dynamic field and there are ongoing discovery processes. The focus of treatment for [colorectal cancer](https://www.withpower.com/clinical-trials/colorectal-cancer) over the past century was on chemotherapy. This process culminated with the advent of chemotherapy, which was not associated with many of the side effects we are nowadays familiar with. This process culminated in the development of targeted drugs as well as antibody therapy. One of the most recent aspects of this field was the development of vaccines; these were not as successful as the previous cancer vaccines, such as the Sipuleucel-T-based vaccine and the Rotarix-derived vaccine.
Findings from a recent study suggest a role for genetic factors in the etiology of colorectal cancer with a hereditary susceptibility component, but the extent of the genetic contribution is not sufficient to explain the observed trends in frequency and age-adjusted incidence of colorectal cancer by race.